Immunotherapy Efficacy and Safety of Programmed Cell Death 1 (PD-1) versus Programmed Death Ligand-1 (PD-L1) Inhibitors in Pan-Cancer Patients: A Systematic Review and Meta-Analysis

2019 ◽  
Author(s):  
Jianchun Duan ◽  
Longgang Cui ◽  
Xiaochen Zhao ◽  
Hua Bai ◽  
Guoqiang Wang ◽  
...  
Keyword(s):  
Systematic Review ◽  
Cell Death ◽  
Programmed Cell Death ◽  
Cancer Patients ◽  
Meta Analysis ◽  
Efficacy And Safety ◽  
Programmed Death Ligand 1 ◽  
Programmed Death ◽  
Programmed Cell Death 1 ◽  
Pan Cancer

scholarly journals The Value of Programmed Death Ligand 1 Expression in Cancer Patients Treated with Neoadjuvant Chemotherapy

2019 ◽  
Vol 19 (4) ◽  
pp. 277 ◽  
Author(s):  
Malika Al-Dughaishi ◽  
Asem Shalaby ◽  
Khawla Al-Ribkhi ◽  
Ammar Boudaka ◽  
Mohamed-Rachid Boulassel ◽  
...  
Keyword(s):  
Cell Death ◽  
Neoadjuvant Chemotherapy ◽  
Programmed Cell Death ◽  
Cancer Patients ◽  
Cell Activity ◽  
Programmed Death Ligand 1 ◽  
Tumour Immunity ◽  
Programmed Death ◽  
Programmed Cell Death 1

Programmed death ligand 1 (PD-L1) is an inhibitory molecule expressed by cancer cells to supress T-cell activity and escape anti-tumour immunity. The role of PD-L1 in cancer has been studied extensively as it is considered an important immune checkpoint against immune over-activation through its interaction with Programmed death receptor 1 (PD-1) expressed on activated lymphocytes. PD-L1 expression was found to be enhanced by chemotherapy through different proliferation pathways. However, the predictive and prognostic value for PD-L1 expression in cancer patients treated with neoadjuvant chemotherapy (NAC) is not yet established. This review focused on the potential effects of chemotherapy on PD-L1 expression and the role of PD-L1 as a prognostic and predictive marker in NAC-treated cancer patients. In addition, the potential use of this marker in clinical practice is discussed.Keywords: Programmed Cell Death 1 Ligand 1; Programmed Cell Death 1 Receptor; Neoadjuvant Therapy; Cancer.

Risk of fatigue in cancer patients treated with anti programmed cell death-1/anti programmed cell death ligand-1 agents: a systematic review and meta-analysis

Immunotherapy ◽  
2018 ◽  
Vol 10 (15) ◽  
pp. 1303-1313
Author(s):  
Matteo Santoni ◽  
Alessandro Conti ◽  
Sebastiano Buti ◽  
Melissa Bersanelli ◽  
Laura Foghini ◽  
...  
Keyword(s):  
Systematic Review ◽  
Cell Death ◽  
Programmed Cell Death ◽  
Cancer Patients ◽  
Meta Analysis ◽  
Programmed Cell Death 1

scholarly journals Efficacy and safety profiles of programmed cell death-1/programmed cell death ligand-1 inhibitors in the treatment of triple-negative breast cancer: A comprehensive systematic review

2019 ◽  
Vol 13 (2) ◽  
Author(s):  
Gilbert Lazarus ◽  
Jessica Audrey ◽  
Anthony William Brian Iskandar
Keyword(s):  
Breast Cancer ◽  
Systematic Review ◽  
Cell Death ◽  
Programmed Cell Death ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Therapeutic Effects ◽  
Efficacy And Safety ◽  
Programmed Cell Death 1 ◽  
Grade 3

Triple-negative breast cancer (TNBC) is associated with worse prognosis, with limited treatment regiments available and higher mortality rate. Immune checkpoint inhibitors targeting programmed cell death-1 (PD-1) or programmed cell death-ligand 1 (PD-L1) showed great potentials in treating malignancies and may serve as potential therapies for TNBC. This systematic review aims to evaluate the efficacy and safety profiles of PD-1/PD-L1 inhibitors in the treatment of TNBC. Literature search was performed via PubMed, EBSCOhost, Scopus, and CENTRAL databases, selecting studies which evaluated the use of anti-PD-1/PDL1 for TNBC from inception until February 2019. Risk of bias was assessed by the Newcastle-Ottawa Scale (NOS). Overall, 7 studies evaluating outcomes of 1395 patients with TNBC were included in this systematic review. Anti-PD-1/PD-L1 showed significant antitumor effect, proven by their promising response (objective response rate (ORR), 18.5-39.4%) and survival rates (median overall survival (OS), 9.2-21.3 months). Moreover, anti- PD-1/PD-L1 yielded better outcomes when given as first-line therapy, and overexpression of PD-L1 in tumors showed better therapeutic effects. On the other hands, safety profiles were similar across agents and generally acceptable, with grade ≥3 treatment- related adverse effects (AEs) ranging from 9.5% to 15.6% and no new AEs were experienced by TNBC patients. Most grade ≥3 AEs are immune-mediated, which are manifested as neutropenia, fatigue, peripheral neuropathy, and anemia. PD-1/PD-L1 inhibitors showed promising efficacy and tolerable AEs, and thus may benefit TNBC patients. Further studies of randomized controlled trials with larger populations are needed to better confirm the potential of these agents.

Sign in / Sign up

Export Citation Format

Share Document